BVNKF
Price:
$28.13
Market Cap:
$15.83B
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN (freeze-dried) that has completed Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase II clinical trial for the treatment of SARS-CoV-2; and TAEK-VAC, which is in Phase I/II ...[Read more]
Industry
Biotechnology
IPO Date
2010-10-15
Stock Exchange
PNK
Ticker
BVNKF
According to Bavarian Nordic A/S’s latest financial reports and current stock price. The company's current ROE is 10.75%. This represents a change of 299.69% compared to the average of 2.69% of the last 4 quarters.
The mean historical ROE of Bavarian Nordic A/S over the last ten years is -1.12%. The current 10.75% ROE has changed -1062.93% with respect to the historical average. Over the past ten years (40 quarters), BVNKF's ROE was at its highest in in the September 2017 quarter at 12.35%. The ROE was at its lowest in in the March 2016 quarter at -10.62%.
Average
-1.12%
Median
1.79%
Minimum
-18.59%
Maximum
14.27%
Discovering the peaks and valleys of Bavarian Nordic A/S ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 376.98%
Maximum Annual ROE = 14.27%
Minimum Annual Increase = -393.65%
Minimum Annual ROE = -18.59%
Year | ROE | Change |
---|---|---|
2023 | 14.27% | -393.65% |
2022 | -4.86% | -22.91% |
2021 | -6.30% | -211.15% |
2020 | 5.67% | -130.50% |
2019 | -18.59% | 12.00% |
2018 | -16.60% | -329.39% |
2017 | 7.24% | 376.98% |
2016 | 1.52% | -65.73% |
2015 | 4.43% | 113.67% |
2014 | 2.07% | -143.28% |
The current ROE of Bavarian Nordic A/S (BVNKF) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
1.04%
5-year avg
-1.96%
10-year avg
-1.12%
Bavarian Nordic A/S’s ROE is greater than AN2 Therapeutics, Inc. (-57.63%), greater than Miromatrix Medical Inc. (-70.01%), greater than Inhibikase Therapeutics, Inc. (-350.62%), greater than PMV Pharmaceuticals, Inc. (-24.20%), greater than Anebulo Pharmaceuticals, Inc. (-184.40%), greater than Molecular Partners AG (-39.16%), greater than Mineralys Therapeutics, Inc. (-55.92%), greater than Pharvaris N.V. (-38.27%), greater than PepGen Inc. (-60.17%), greater than Edgewise Therapeutics, Inc. (-26.83%), greater than Rallybio Corporation (-77.39%), less than Opthea Limited (360.15%), greater than Replimune Group, Inc. (-53.12%), greater than Nuvalent, Inc. (-28.63%), greater than Ventyx Biosciences, Inc. (-54.94%), less than Ascendis Pharma A/S (212.63%), less than United Therapeutics Corporation (19.22%), greater than Aura Biosciences, Inc. (-41.57%), greater than Axcella Health Inc. (-620.40%), less than H-CYTE, Inc. (207.47%), greater than Antibe Therapeutics Inc. (-49.77%),
Company | ROE | Market cap |
---|---|---|
-57.63% | $39.99M | |
-70.01% | $92.95M | |
-350.62% | $155.21M | |
-24.20% | $83.31M | |
-184.40% | $37.86M | |
-39.16% | $219.11M | |
-55.92% | $621.09M | |
-38.27% | $1.20B | |
-60.17% | $143.75M | |
-26.83% | $3.05B | |
-77.39% | $42.32M | |
360.15% | $486.27M | |
-53.12% | $1.02B | |
-28.63% | $6.75B | |
-54.94% | $130.81M | |
212.63% | $7.76B | |
19.22% | $16.65B | |
-41.57% | $443.97M | |
-620.40% | $0 | |
207.47% | $624.98K | |
-49.77% | $11.45M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Bavarian Nordic A/S using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Bavarian Nordic A/S or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Bavarian Nordic A/S's ROE?
How is the ROE calculated for Bavarian Nordic A/S (BVNKF)?
What is the highest ROE for Bavarian Nordic A/S (BVNKF)?
What is the 3-year average ROE for Bavarian Nordic A/S (BVNKF)?
What is the 5-year average ROE for Bavarian Nordic A/S (BVNKF)?
How does the current ROE for Bavarian Nordic A/S (BVNKF) compare to its historical average?